MAVA-LTE: Mavacamten provides sustained clinical benefits for up to five years in obstructive hypertrophic cardiomyopathy

Heart, Artery and Coronary Diseases

Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

Circ Genom Precis Med

Bilen O, Adler AS, Bastiaenen R, MacNamara JP, Paratz ED, Maor E, Arad M, Gold ME, Patel N, Pruett C, Burford E, Arora G, Maksabedian Hernandez EJ, Han X, Schuler P, Sandler B, Li L, Tian D, Arora P

doi: 10.1161/CIRCGEN.125.005502

Atrial FibrillationFurther Publications

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data

J Am Heart Assoc

Fath AR, Aglan A, Naidu SS, Mader MJ, Chilton RJ, Elgendy IY, Maron MS, Rowin EJ

doi: 10.1161/JAHA.125.045994

Heart, Artery and Coronary Diseases

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial

JAMA Cardiol

Lewis GD, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, de Barros Correia E, Dybro AM, Kulac IJ, Lakdawala NK, Mann A, Maron MS, McGinnis S, Nair A, Newlands C, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Elliott PM, MAPLE-HCM Investigators

doi: 10.1001/jamacardio.2026.1730

Further Publications

Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy

JAMA Cardiol

Hafeez N, Claggett BL, Owens AT, Helms AS, Saberi S, Lampert R, Stendahl JC, Ashley EA, Parikh VN, Lakdawala NK, Ingles J, Olivotto I, Ho CY, Taylor MR, Khan SS, Day SM

doi: 10.1001/jamacardio.2025.4869

Further Publications

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial

JAMA Cardiol

Jering KS, Manafi A, Claggett BL, Fontana M, Gillmore JD, Bulwer BE, Roshanali F, Prasad N, Jay PY, Solomon SD, Skali H

doi: 10.1001/jamacardio.2026.3390

Heart, Artery and Coronary Diseases

Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial

JAMA Cardiol

Jering KS, Manafi A, Claggett BL, Bart NK, Prasad N, Birkhoelzer SM, Hamatani Y, Lairez O, Tsujita K, Gillmore JD, Maurer MS, Jay PY, Skali H, Fontana M, Solomon SD

doi: 10.1001/jamacardio.2026.2992

Heart, Artery and Coronary Diseases

Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis

Mayo Clin Proc

Nagaraja V, Lewis BR, Korsapati H, Mene-Afejuku TO, Dillon JJ, Cheungpasitporn W, Gharacholou M, Reeder G, Hibbert B, Best P, Prasad A, Singh M

doi: 10.1016/j.mayocp.2025.11.016

Further Publications

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

JAMA Cardiol

Soman P, Cuddy SAM, Gillmore JD, Sarswat N, Judge DP, Cappelli F, Stern LK, Wright R, Akinboboye O, Obici L, Bhatt K, Xiong K, Castaño A, Chen C, Falvey H, Pecoraro ML, Tamby JF, Sinha U, Fox JC, Shah K, Grodin JL, Ambardekar AV, Alexander KM, Khouri MG, Cheng RK

doi: 10.1001/jamacardio.2026.0819

Further Publications

Sex Differences in Characteristics and Outcomes Among Patients With Hypertrophic Cardiomyopathy: Insights From the REVEAL-HCM Study

J Am Heart Assoc

Nakamura M, Abe H, Ueda Y, Kitaoka H, Sakata Y, Dohi K, Tokita Y, Kato T, Matsushima S, Amano M, Kitai T, Okada A, Furukawa Y, Tamura T, Hayashida A, Ando K, Yuda S, Inoko M, Kadota K, Abe Y, Iwakura K, Kitamura T, Masuda J, Ohara T, Omura T, Tanigawa T, Nakamura K, Nakatsuka K, Nishimura K, Izumi C, REVEAL‐HCM Investigators

doi: 10.1161/JAHA.125.046708

Related content

Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

Mavacamten in Obstructive Hypertrophic Cardiomyopathy: National Insights on Access and Safety Profile From Real-World Data

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial

Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial

Left Atrial Structure and Function, Clinical Outcomes, and Efficacy of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: A Secondary Analysis of the HELIOS-B Randomized Clinical Trial

Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis

Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical Trial

Sex Differences in Characteristics and Outcomes Among Patients With Hypertrophic Cardiomyopathy: Insights From the REVEAL-HCM Study